- Former Lundbeck Executive Brings Strong Commercial Experience and Extensive Pharmaceutical Industry Network -

Stockholm, May 29, 2012 – InDex Pharmaceuticals today announced that Stig Løkke Pedersen has been appointed as a new member of the Board of Directors. Mr. Pedersen brings to InDex Pharmaceuticals over 25 years of longstanding life sciences industry experience in commercial operations and leadership.

Mr. Pedersen previously served as Executive Vice President of Commercial Operations at H. Lundbeck A/S. He joined Lundbeck in January 1992, being responsible for the company's business development activities. Following a period as Managing Director of Lundbeck Netherlands, he became part of the corporate senior management in 1998. Mr. Pedersen was appointed Executive Vice President in April 2003 and held the position as EVP for Commercial Operations from 2007 until June 2011, when he resigned from his position at Lundbeck. Mr. Pedersen is a Partner at Executive Capital A/S and serves as the Chairman of the Board of Directors at Chemometec A/S and Nuevolution A/S. He is a member of the Board of Directors at MSI Methylation Sciences Inc. and a member of the Advisory Board of Atrium Partners A/S and JSB-Partners, as well as an advisor to the Lundbeck Foundation.

“We are very happy to welcome Mr. Pedersen to our Board of Directors,” says Jesper Wiklund, CEO of InDex Pharmaceuticals. “His broad experience in commercial operations and corporate business development will bring significant strength to InDex and its continued growth. His deep and relevant knowledge will provide us with invaluable insights and guidance as we move our lead drug candidate Kappaproct® through phase III and towards the market.”

###

Media Inquiries:
akampion
Dr. Ludger Wess or Ines-Regina Buth
Tel.: +49 (0)40 88 16 59 64/ +49 (0)30 2363 2768
info(at)akampion.com

About InDex Pharmaceuticals
InDex Pharmaceuticals is a biopharmaceutical company focusing on the discovery and development of immunology-based treatments exclusively addressing disease states with a high unmet medical need. InDex Pharmaceuticals is also dedicated to personalized medicine and is developing companion diagnostics that will allow for the selection of only those patients likely to respond to a treatment. Kappaproct®, the lead drug candidate of InDex, is currently in a phase III study as a treatment for chronic active, treatment refractory ulcerative colitis. In 2009, InDex Pharmaceuticals launched the diagnostic test DiBiCol® in Sweden. DiBiCol differentiates between ulcerative colitis and Crohn’s disease, the two major forms of inflammatory bowel disease.
InDex Pharmaceuticals was founded in 2000 and is located in Stockholm, Sweden.
For additional information about InDex Pharmaceuticals please visit www.indexpharma.com.

InDex Pharmaceuticals AB
Jesper Wiklund, CEO
Scheeles väg 2
SE-171 77 Stockholm, Sweden

Phone: Tel: +46 8 508 847 35/ +46 (0)733 59 05 53
jesper.wiklund(at)indexpharma.com

This release was published on openPR.